Table 5 Best overall response to ASP3026 in the dose-expansion cohort
Parameter | Expansion cohort ASP3026 525 mg (n = 16) |
|---|---|
Best overall responsea, n (%) | |
Complete response | 0 |
Partial response | 8 (50) |
Stable disease | 7 (44) |
Progressive disease | 0 |
Unable to evaluate | 1 (6) |
Objective response (complete response + partial response) | |
n (%) | 8 (50) |
95 % CIb | 25–75 % |